BIA submission to the DWP consultation on improving outcomes for members of DC schemes

As discussion around the Autumn Budget heats up, BIA is leading a unified call to the Chancellor to back the science, the entrepreneurs and the life sciences industry that can fuel transformational growth for the UK economy. Our sector letter highlights key growth levers and indeed the barriers that hold the sector back in already challenging global conditions. 

AAVantgarde's Stargardt disease and Usher syndrome Ib programmes address the root genetic causes of devastating conditions and offer hope of improvement to patients and families living with progressive vision loss.

The UK biotech financing numbers for Q3 are out, showing validation of UK assets but a sector under strain from prolonged global headwinds. Time to double down on investment in innovation as a driver for growth and deploy Industrial Strategy plans with urgency.

LifeArc and the Gates Foundation are funding seven ground-breaking new projects launched to lower the cost of monoclonal antibody production to make them more accessible globally.

New BIA data shows venture capital activity slowing amid the longest global funding drought in the sector. Despite a landmark M&A deal validating UK science, the figures signal a fragile moment that needs urgent government action.